Leatherhead, UK – Oct 22, 2024 – Zoetis UK Ltd today announced a further delay in the supply of Equip Artervac, due to a manufacturing issue. It is now anticipated that the product will be available in June 2025.
Zoetis sincerely apologises for the further disruption and inconvenience that this may cause and will provide further information as soon as it becomes available.
Equip Artervac is a part of the Zoetis Equip range of vaccines. It is indicated for the active immunisation for horses against equine viral arteritis (EVA) to reduce the clinical signs and shedding of the virus in nasal secretions following infection.
For further information contact your Zoetis Account Manager or call Head Office on 0345 300 8034.
About Zoetis
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers and ranchers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $8.5 billion in 2023 with approximately 14,100 employees. For more information, visit www.zoetis.com.